Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.28 and traded as low as $0.21. Northwest Biotherapeutics shares last traded at $0.23, with a volume of 3,564,085 shares changing hands.
Northwest Biotherapeutics Stock Down 1.2 %
The company has a market capitalization of $288.44 million, a P/E ratio of -2.59 and a beta of -0.67. The business has a fifty day moving average price of $0.25 and a 200 day moving average price of $0.27.
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last released its earnings results on Monday, March 31st. The biotechnology company reported ($0.02) EPS for the quarter. The business had revenue of $0.23 million during the quarter.
About Northwest Biotherapeutics
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
See Also
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
